SCHEMBL273609

SCHEMBL273609

CCCCOC(=O)c1ccc(N=C=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.62
LMNA P02545 3/20 0.62
CYP1A2 P05177 3/20 0.62
TSHR P16473 2/20 0.62
CYP2C19 P33261 2/20 0.62
CYP2D6 P10635 2/20 0.62
MAPK1 P28482 1/20 0.62
NR1H2 P55055 1/20 0.62
RNASEL Q05823 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
CYP3A4 P08684 2/20 0.60
CYP2C9 P11712 1/20 0.60
PDE4D Q08499 1/20 0.60
HPGD P15428 1/20 0.55
RECQL P46063 1/20 0.55
NPC1 O15118 1/20 0.54
MAPT P10636 1/20 0.54
RAB9A P51151 1/20 0.54
ALDH1A1 P00352 1/20 0.54
STS P08842 7/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9751347 0.91 TDP1 (0.55) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL2863947 0.88 ESR1 (0.62) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL813539 0.87 TSHR (0.47) ESR1LMNACYP1A2TSHRCYP2C19
Phenethyl Isocyanate SCHEMBL7528231 0.85 TSHR (0.46) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL76337 0.84 MAPT (0.58) ESR1LMNACYP1A2SMN1; SMN2CYP3A4
SCHEMBL37476 0.83 ESR1 (0.85) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL11557416 0.83 CYP1A2 (0.50) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL9420474 0.83 SERPINE1 (0.49) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL9420499 0.83 SERPINE1 (0.49) ESR1LMNACYP1A2TSHRCYP2C19
SCHEMBL9420514 0.83 SERPINE1 (0.49) ESR1LMNACYP1A2TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026104221-A1 PROCESS FOR PREPARING OF ORGANIC CARBAMOYL AZIDES All4Labels Group GmbH (DE) 2026-05-21 WO disclosed
CN-117402418-B High-wear-resistance rubber hose and preparation method thereof 河北润驰流体科技有限公司 2024-02-27 CN disclosed
CN-117402418-A High-wear-resistance rubber hose and preparation method thereof 河北润驰流体科技有限公司 2024-01-16 CN disclosed
EP-2623087-B1 Dental composite materials containing tricyclic plasticisers VOCO GMBH (DE) 2019-07-17 EP disclosed
EP-2623086-B1 Curable mixture comprising plasticisers with a polyalicyclic structure element for use in the production of dental materials. VOCO GMBH (DE) 2019-07-10 EP disclosed
US-9314408-B2 Dental composite materials comprising tricyclic plasticizers VOCO GMBH (DE) 2016-04-19 US disclosed
US-20160068559-A1 Modulators of Histone Methyltransferase, and Methods of Use Thereof Epizyme, Inc. 2016-03-10 US disclosed
US-9029343-B2 Modulators of histone methyltransferase, and methods of use thereof Epizyme, Inc. (US) 2015-05-12 US disclosed
US-20130310333-A1 Modulators of Histone Methyltransferase, and Methods of Use Thereof Epizyme, Inc. (US) 2013-11-21 US disclosed
EP-2646455-A2 MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2013-10-09 EP disclosed
EP-0832650-A2 Use of serotonin 5-HT1F agonists for the prevention of migraine ELI LILLY AND COMPANY (US) 1998-04-01 EP disclosed
WO-1998011895-A1 A METHOD FOR THE PREVENTION OF MIGRAINE ELI LILLY AND COMPANY (US) 1998-03-26 WO disclosed
EP-0824917-A2 Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis ELI LILLY AND COMPANY (US) 1998-02-25 EP disclosed
WO-1998006402-A1 TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS ELI LILLY AND COMPANY (US) 1998-02-19 WO disclosed
US-5708008-A TREATMENT OF MIGRAINE ELI LILLY AND COMPANY (US) 1998-01-13 US disclosed
EP-0816309-A1 Scavenger assisted combinatorial process for preparing libraries of urea and thiourea compounds ELI LILLY AND COMPANY (US) 1998-01-07 EP disclosed
US-5627181-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DE) 1997-05-06 US disclosed
WO-1997000244-A1 PROCESS FOR PARALLEL SYNTHESIS OF A NON-PEPTIDE LIBRARY ELI LILLY AND COMPANY (US) 1997-01-03 WO disclosed
WO-1996029075-A1 5-SUBSTITUTED-3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)- AND 3-(PIPERIDIN-4-YL)-1H-INDOLES: NEW 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 1996-09-26 WO disclosed
EP-0733628-A1 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists ELI LILLY AND COMPANY (US) 1996-09-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068559-A1 Modulators of Histone Methyltransferase, and Methods of Use Thereof EHMT1, EHMT2, HNMT ESR1 4146/4885LMNA 1712/4885CYP1A2 4214/4885
US-20130310333-A1 Modulators of Histone Methyltransferase, and Methods of Use Thereof EHMT1, EHMT2, HNMT ESR1 4146/4885LMNA 1712/4885CYP1A2 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.